Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Incyte Corporation
OHSU Knight Cancer Institute
Fate Therapeutics
Hoffmann-La Roche
Tocagen Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
sigma-tau i.f.r. S.p.A.
Incyte Corporation